粪便免疫化学检测在监测性结肠镜检查中检出进展期肿瘤的诊断效能
这项前瞻性研究纳入766例接受监测性结肠镜检查的患者,在检查前90天内完成2样本粪便免疫化学检测(FIT),评估不同粪便血红蛋白阈值(2–80 μg/g)下FIT对进展期肿瘤(结直肠癌或进展期腺瘤)的敏感性,并分析检出进展期肿瘤的相关因素。
要点
- 中危个体FIT对进展期肿瘤的敏感性从2 μg/g时的73.5%降至80 μg/g时的10.2%。
- 高危个体FIT敏感性从2 μg/g时的70.6%降至80 μg/g时的11.8%。
- 全队列中年龄(OR 1.03)和FIT血红蛋白≥10 μg/g(OR 1.81)与检出进展期肿瘤相关。
核心结论
- 监测性结肠镜检查前使用FIT可为临床医生提供进展期肿瘤风险信息,提出了一种可对个体进行分诊、促进内镜资源更高效管理的方法可能性。
研究设计与样本
- 前瞻性研究,在三级医疗中心开展,共纳入766例患者(中位年龄66.1岁,四分位距58.1–72.9;男性49.9%),在监测性结肠镜检查前90天内完成2样本FIT(OC-Sensor,Eiken Chemical Company)。
主要发现
- 全队列中进展期肿瘤检出率为8.6%(66/766,包括5例结直肠癌)。
- 中危个体(既往腺瘤史或结直肠癌显著家族史)FIT对进展期肿瘤的敏感性从2 μg/g粪便时的73.5%降至80 μg/g粪便时的10.2%。
- 高危情况(确诊/疑似遗传性综合征或既往结直肠癌)FIT敏感性相似,从最低阳性阈值2 μg/g粪便时的70.6%降至80 μg/g粪便时的11.8%。
- 全队列中与监测性结肠镜检查检出进展期肿瘤相关的独立变量为年龄(OR 1.03;95%CI 1.00–1.06)和FIT血红蛋白结果≥10 μg/g粪便(OR 1.81;95%CI 1.04–3.16)。
关键数值与推荐
- 中危个体FIT对进展期肿瘤的敏感性:2 μg/g粪便时为73.5%,80 μg/g粪便时为10.2%。
- 高危情况FIT对进展期肿瘤的敏感性:2 μg/g粪便时为70.6%,80 μg/g粪便时为11.8%。
- 年龄与检出进展期肿瘤相关(OR 1.03;95%CI 1.00–1.06)。
- FIT血红蛋白≥10 μg/g粪便与检出进展期肿瘤相关(OR 1.81;95%CI 1.04–3.16)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: An increasing burden on health care resources has resulted in a backlog of individuals requiring colonoscopy, with delays in surveillance possibly detrimental for individuals at increased risk of colorectal cancer (CRC). This study investigated the use of a 2-sample fecal immunochemical test (FIT) to establish those most likely to have advanced neoplasia (AN) and in need of prioritized surveillance colonoscopy. METHODS: This was a prospective study conducted in the tertiary care setting. Participants completed a 2-sample FIT (OC-Sensor, Eiken Chemical Company) within 90 days of surveillance colonoscopy. The sensitivity of FIT for detection of AN (CRC or advanced adenoma) in moderate- and high-risk individuals was determined at fecal hemoglobin thresholds between 2 and 80 μg/g feces. RESULTS: A total of 766 patients were included (median age, 66.1 years [interquartile range, 58.1-72.9]; 49.9% male), with AN detected in 8.6% (66/766, including 5 CRC). For moderate-risk individuals (with prior history of adenoma or a significant family history of CRC), sensitivity of FIT for AN ranged from 73.5% at 2 μg/g feces, to 10.2% at 80 μg/g feces. For high-risk conditions (confirmed/suspected genetic syndromes or prior CRC), sensitivity of FIT was similar, ranging from 70.6% at the lowest positivity threshold of 2 μg/g feces, to 11.8% at 80 μg/g feces. Independent variables in the whole cohort for association with detection of AN at surveillance colonoscopy were age (odds ratio, 1.03; 95% confidence interval, 1.00-1.06) and FIT hemoglobin result ≥10 μg/g feces (odds ratio, 1.81; 95% confidence interval, 1.04-3.16). CONCLUSIONS: The use of FIT before surveillance colonoscopy provides clinicians with insights into the risk of AN. This raises the possibility of a method to triage individuals, facilitating the more efficient management of endoscopic resources.
引用
- Berwald G, Young GP, Cock C, et al. The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy. Clin Gastroenterol Hepatol. 2023. PMID: 37743036. doi:10.1016/j.cgh.2023.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。